|Bid||9.03 x 800|
|Ask||19.11 x 1100|
|Day's range||18.05 - 19.02|
|52-week range||13.70 - 29.90|
|Beta (3Y monthly)||0.82|
|PE ratio (TTM)||N/A|
|Earnings date||7 Mar 2018 - 12 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||31.33|
STOUGHTON, Mass., Nov. 12, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain.
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -127.27% and -6.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Canton, Massachusetts-based company said it had a loss of 50 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 25 cents per share. The results did not meet ...
Net Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017Thirteen exclusive ER oxycodone formulary wins announced for.
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STOUGHTON, Mass., Oct. 29, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the publication of “Evaluation of the oral human abuse potential of Oxycodone.
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
STOUGHTON, Mass., Oct. 17, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
STOUGHTON, Mass., Sept. 28, 2018-- Collegium Pharmaceutical, Inc. today announced that management will present at the following investor conference in October:. The Cantor Global Healthcare Conference ...
Collegium Pharmaceutical’s net loss decreased from $21.12 million in the second quarter of 2017 to $13.06 million in the second quarter of 2018, which translated into a net loss per share of $0.40 in the second quarter as compared with a net loss per share of $0.72 in the second quarter of 2017. In August 2018, of the total eight analysts covering Collegium Pharmaceutical, three analysts have given the stock a “strong buy” rating, and five analysts have given Collegium Pharmaceutical a “buy” rating. The mean rating for Collegium Pharmaceutical stock is 1.63 with a target price of $31.67.
Collegium Pharmaceutical (COLL) is a specialty pharmaceutical company focused on bringing to market products for people suffering from pain. In January 2018, Collegium began commercializing Nucynta products. Collegium Pharmaceutical generated total revenues of $73.06 million in the second quarter of 2018 as compared with $3.56 million in the second quarter of 2017.
The US government is taking steps to address the opioid epidemic and rapidly rising addiction levels in the country. On August 16, President Trump asked the Attorney General to start filing federal lawsuits against certain companies that supply opioids to hospitals. In this series, we’ll analyze the financial performance, products, analysts’ views, valuation metrics, and the stock performance of Insys Therapeutics (INSY), Cara Therapeutics (CARA), Collegium Pharmaceutical (COLL), and Pacira Pharmaceuticals (PCRX).
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 65.91% and 4.06%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
While small-cap stocks, such as Collegium Pharmaceutical Inc (NASDAQ:COLL) with its market cap of US$879.63m, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
On a per-share basis, the Canton, Massachusetts-based company said it had a loss of 57 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...